Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Insights - The collaboration with GSK represents a significant opportunity for the company, enhancing its global development strategy and improving cash flow through upfront and milestone payments [2][9]. - The company is well-positioned in the siRNA drug discovery and development field, gaining international recognition and leveraging GSK's resources for clinical development and commercialization [2][9]. - The small nucleic acid drugs are a key focus area, with a broad pipeline addressing various diseases, indicating a promising market outlook [9]. Financial Projections - Revenue is projected to grow from 1.29 billion CNY in 2024 to 2.85 billion CNY in 2027, with growth rates of 13.3%, 23.1%, 38.0%, and 29.5% respectively [3][10]. - The net profit attributable to shareholders is expected to improve from -201 million CNY in 2024 to -174 million CNY in 2027, with growth rates of 38.8%, 7.5%, 2.1%, and 4.8% respectively [3][10]. - Earnings per share (EPS) is projected to gradually improve from -0.54 CNY in 2024 to -0.46 CNY in 2027 [3][10]. Market Position and Strategy - The company has established a comprehensive pipeline for small nucleic acid drugs, targeting conditions such as IgA nephropathy, hyperuricemia, cancer, and cardiovascular diseases [9]. - The collaboration with GSK is expected to accelerate the internationalization of the company's pipeline and lay a solid foundation for future commercialization efforts [2][9].